Page 11 - Active Biotech News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share: AUSTIN, Texas, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced the appointment of An van Es-Johansson, M.D., to its Board of Directors, effective immediately, where she will serve as a member of the Nominating and Governance Committee. Dr. van Es-Johansson brings over 30 years of experience in executive and clinical development roles in the pharmaceutical industry. Dr. van Es-Johansson will succeed Emmett Cunningham who is resigning his Board position to focus on other ...

Investegate announcements from Active Biotech, Active Biotech Year-end report January – December 2020 

Share this article Share this article PALM BEACH, Fla., Jan. 27, 2021 /PRNewswire/ -- The antivirals market consists of sales of antiviral drugs and related services. Antiviral drugs reduce the replication of viruses at different stages. Various type of viral infections for which antiviral drugs are used include HIV, herpes, hepatitis and influenza viruses and, of course, COVID-19. Millions of people across the globe are affected by the CORONA / COVID-19 virus. The pandemic has put massive pressure on medicine safety stocks. Healthcare providers are using every possible tool to treat COVID-1...

Autoimmune Treatment Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 New York, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Autoimmune Treatment Market Research Report by Product, by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05913302/?utm_source=GNW The Global Autoimmune Treatment Market is expected to grow from USD 149,595.74 Million in 2019 to USD 222,840.11 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) o...

Active Biotech Receive Milestone Payment From Neotx PRESS RELEASE, Lund Sweden, December 11, 2020 - Active Biotech (NASDAQ STOCKHOLM: ACTI) Active Biotech AB (publ) today announce a milestone payment of USD 750 000 from the partner NeoTX Therapeutics (NeoTX) under the terms of license agreement on the immunotherapy naptumomab. Based on preclinical data and the previous clinical experience of naptumomab, a phase Ib/II study in patients with advanced solid tumors was initiated by NeoTX, in cooperation with AstraZeneca, in 2019. The study is currently ongoing, and the results from the dose esc...